ArticleAnnals of translational medicine2019
Development and validation of a novel nomogram for predicting distant metastasis-free survival among breast cancer patients.
Article in Annals of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Metastatic patterns and survival outcomes across molecular subtypes in a large cohort of breast cancer patients from the Shiraz breast cancer registry.Discover oncology · 2025Article
- Developing a nomogram model and prognostic analysis of nasopharyngeal squamous cell carcinoma patients: a population-based study.Journal of cancer research and clinical oncology · 2023Article
- Article
- Options of locoregional therapy for primary foci of breast cancer influence the rate of nonregional lymph node metastasis in N2-N3 status patients: a SEER database analysis.Breast cancer (Tokyo, Japan) · 2023Article
- Implications for surveillance for breast cancer patients based on the internally and externally validated BRENDA-metastatic recurrence score.Breast cancer research and treatment · 2023Article
- Prediction of bone metastasis risk of early breast cancer based on nomogram of clinicopathological characteristics and hematological parameters.Frontiers in oncology · 2023Article
- The biomarkers related to immune infiltration to predict distant metastasis in breast cancer patients.Frontiers in genetics · 2023Article
- Comparison of the Characteristics and Prognosis Between Very Young Women and Older Women With Breast Cancer: A Multi-Institutional Report From China.Frontiers in oncology · 2022Article
- Article
- Multi-Omics Profiling Suggesting Intratumoral Mast Cells as Predictive Index of Breast Cancer Lung Metastasis.Frontiers in oncology · 2021Article
- Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data.Annals of translational medicine · 2021Article
- Construction of nomograms for nasopharyngeal carcinoma containing primary tumor size and SEER stage.Translational cancer research · 2020Article
- Development and validation of a nomogram in survival prediction among advanced breast cancer patients.Annals of translational medicine · 2020Article
- Clinicopathological characteristics and prediction of cancer-specific survival in large cell lung cancer: a population-based study.Journal of thoracic disease · 2020Article
- Construction of a MicroRNA-Based Nomogram for Prediction of Lung Metastasis in Breast Cancer Patients.Frontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDistant metastasis (DM) from breast cancer has a poor prognosis. Our objective was to develop and validate a nomogram to predict individual distant metastasis-free survival (DMFS) and risk stratification in non-metastatic breast cancer patients.
methodsA nomogram was based on an analysis of 1,201 breast cancer patients treated at Sun Yat-sen Memorial Hospital from 2001 to 2014. Using univariate and multivariate analyses to identify the predictors, this model was externally validated in an independent cohort of 538 patients from the Guangdong General Hospital between 2004 and 2012. The predictive discrimination and calibration ability of this nomogram were assessed using concordance index (C-index), risk group stratification, and calibration curve.
resultsThe 5-year DMFS in the training and validation cohorts were 95.74% and 91.02%, respectively. On multivariable analysis of training cohort, the prognostic factors in the nomogram comprised age, tumor size, lymph node status, molecular subtype, and lymphovascular invasion (LVI). The C-index of our model was 0.75 [95% confidence interval (CI): 0.67-0.83] for the training cohort and 0.71 (95% CI: 0.64-0.78) for the validation cohort. The calibration curves for 5-year DMFS showed good agreement between the model prediction and actual observation. Based on the risk stratification, Kaplan-Meier curves indicated that the low-risk group had significantly better prognosis than the high-risk group (P<0.001).
conclusionsOur nomogram can provide an individual prediction of 5-year DMFS in non-metastatic breast cancer patients. This prognostic tool may help clinicians to make appropriate treatment regimens and optimal surveillance plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.